Literature DB >> 25310122

Defining and analyzing retention-in-care among pregnant and breastfeeding HIV-infected women: unpacking the data to interpret and improve PMTCT outcomes.

Nigel C Rollins1, Renaud Becquet, Joanna Orne-Gliemann, Sam Phiri, Chika Hayashi, April Baller, Nathan Shaffer.   

Abstract

The prevent mother-to-child transmission (PMTCT) "cascade" describes the programmatic steps for pregnant and breastfeeding women that influence HIV transmission rates. To this end, HIV-infected pregnant women and mothers need access to health services and adhere to antiretroviral (ARV) prophylaxis or lifetime treatment. Within the cascade, the concept of "retention-in-care" is commonly used as a proxy for adherence to ARV interventions and, even, viral suppression. Yet surprisingly, there is no standard definition of retention-in-care either for the purposes of HIV surveillance or implementation research. Implicit to the concept of retention-in-care is the sense of continuity and receipt of care at relevant time points. In the context of PMTCT, the main challenge for surveillance and implementation research is to estimate effective coverage of ARV interventions over a prolonged period of time. These data are used to inform program management and also to estimate postnatal MTCT rates. Attendance of HIV-infected mothers at clinic at 12-month postpartum is often equated with full retention in PMTCT programs over this period. Yet, measurement approaches that fail to register missed visits, or inconsistent attendance or other missing data in the interval period, fail to capture patterns of attendance and care received by mothers and children and risk introducing systematic errors and bias. More importantly, providing only an aggregated rate of attendance as a proxy for retention-in-care fails to identify specific gaps in health services where interventions to improve retention along the PMTCT cascade are most needed. In this article, we discuss how data on retention-in-care can be understood and analyzed, and what are the implications and opportunities for programs and implementation research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25310122     DOI: 10.1097/QAI.0000000000000355

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  20 in total

1.  Stepped-Wedge Cluster Randomized Controlled Trial to Promote Option B+ Retention in Central Mozambique.

Authors:  James T Pfeiffer; Manuel Napúa; Bradley H Wagenaar; Falume Chale; Roxanne Hoek; Mark Micek; João Manuel; Cathy Michel; Jessica Greenberg Cowan; James F Cowan; Sarah Gimbel; Kenneth Sherr; Stephen Gloyd; Rachel R Chapman
Journal:  J Acquir Immune Defic Syndr       Date:  2017-11-01       Impact factor: 3.731

2.  Assessing Option B+ retention and infant follow-up in Lilongwe, Malawi.

Authors:  Blake M Hauser; William C Miller; Hannock Tweya; Colin Speight; Tiwonge Mtande; Sam Phiri; L M Ball; Mina C Hosseinipour; Irving F Hoffman; Nora E Rosenberg
Journal:  Int J STD AIDS       Date:  2017-07-27       Impact factor: 1.359

3.  Retention in HIV Care Among HIV-Seropositive Pregnant and Postpartum Women in Uganda: Results of a Randomized Controlled Trial.

Authors:  Lora L Sabin; Nafisa Halim; Davidson H Hamer; Elizabeth M Simmons; Sivani Jonnalagadda; Anna Larson Williams; Harriet Chemusto; Allen L Gifford; Rachael Bonawitz; Philip Aroda; Mary DeSilva; Julia Gasuza; Barbara Mukasa; Lisa J Messersmith
Journal:  AIDS Behav       Date:  2020-11

4.  Loss to Follow-Up within the Prevention of Mother-to-Child Transmission Care Cascade in a Large ART Program in Nigeria.

Authors:  Holly E Rawizza; Charlotte A Chang; Beth Chaplin; Isah A Ahmed; Seema T Meloni; Tinuade Oyebode; Bolanle Banigbe; Atiene S Sagay; Isaac F Adewole; Prosper Okonkwo; Phyllis J Kanki
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

5.  Patients' and Providers' Views on Optimal Evidence-Based and Scalable Interventions for Individuals at High Risk of HIV Treatment Failure: Sequential Explorations Among Key Stakeholders in Cape Town, South Africa.

Authors:  Lora L Sabin; Allen L Gifford; Jessica E Haberer; Kelsee Harvey; Natalya Sarkisova; Kyle Martin; Rebecca L West; Jessie Stephens; Clare Killian; Nafisa Halim; Natacha Berkowitz; Karen Jennings; Lauren Jennings; Catherine Orrell
Journal:  AIDS Behav       Date:  2022-02-21

6.  Predictors of postpartum HIV care engagement for women enrolled in prevention of mother-to-child transmission (PMTCT) programs in Tanzania.

Authors:  Melissa H Watt; Cody Cichowitz; Godfrey Kisigo; Linda Minja; Brandon A Knettel; Elizabeth T Knippler; James Ngocho; Preeti Manavalan; Blandina T Mmbaga
Journal:  AIDS Care       Date:  2018-11-22

7.  Measuring retention in HIV care: the impact of data sources and definitions using routine data.

Authors:  Tamsin K Phillips; Catherine Orrell; Kirsty Brittain; Allison Zerbe; Elaine J Abrams; Landon Myer
Journal:  AIDS       Date:  2020-04-01       Impact factor: 4.632

8.  Progress Toward Eliminating Mother to Child Transmission of HIV in Kenya: Review of Treatment Guideline Uptake and Pediatric Transmission at Four Government Hospitals Between 2010 and 2012.

Authors:  Sarah Finocchario-Kessler; Kristine F Clark; Samoel Khamadi; Brad J Gautney; Vincent Okoth; Kathy Goggin
Journal:  AIDS Behav       Date:  2016-11

9.  Mother Infant Retention for Health (MIR4Health): Study Design, Adaptations, and Challenges With PMTCT Implementation Science Research.

Authors:  Ruby N Fayorsey; Duncan Chege; Chunhui Wang; William Reidy; Zachary Peters; Masila Syengo; Chrisostim Barasa; Samuel O Owino; Martin Sirengo; Mark P Hawken; Elaine J Abrams
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

10.  Option B+ in Mozambique: Formative Research Findings for the Design of a Facility-Level Clustered Randomized Controlled Trial to Improve ART Retention in Antenatal Care.

Authors:  Manuel Napúa; James T Pfeiffer; Falume Chale; Roxanne Hoek; Joao Manuel; Cathy Michel; Jessica G Cowan; James F Cowan; Sarah Gimbel; Kenneth Sherr; Stephen Gloyd; Rachel R Chapman
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.